focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,172.00
Bid: 11,500.00
Ask: 12,470.00
Change: 0.00 (0.00%)
Spread: 970.00 (8.435%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Stocks finish lower as ECB stands pat

Thu, 11th Apr 2024 15:56

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

The FTSE 100 closed down 0.47% at 7,923.80 points, while the FTSE 250 experienced a marginal decline of 0.08%, closing at 19,786.87 points.

In currency markets, sterling was last down 0.06% on the dollar, trading at $1.2532, while it strengthened 0.18% against the euro to change hands at €1.1693.

"The FTSE 100 saw a slight increase [earlier] as investors shifted their attention from the higher-than-expected US inflation data to the European Central Bank's interest rate decision," said TickMill market analyst Patrick Munnelly.

"The internationally-focused index saw a slight decline post the ECB announcement, where it held the bank rate at 4%.

"ECB president Christine Lagarde did not commit to a specific policy path."

Munnelly said the ECB's statement indicated that if inflation and monetary policy transmission increased confidence in returning price growth to target, it would be appropriate to reduce monetary policy restrictions.

"Investors inferred that means a rate cut in June is likely.

"However, president Lagarde's comments during the post-meeting press conference left traders uncertain about the future development of policy after June."

Wholesale prices rise modestly in the US, ECB stands pat on rates

In economic news, US wholesale prices saw a modest increase last month, falling slightly short of expectations.

The Department of Labor reported a 0.2% month-on-month rise in seasonally adjusted total final demand prices in March, with food prices climbing by 0.8%.

However, energy prices experienced a 1.6% decline, serving as a partial offset.

On a year-on-year basis, producer prices were up by 2.1%, indicating a steady yet moderate pace of inflation.

"After another sizzling CPI report, producer prices offer some relief for Fed officials who may view the recent price reports as too hot to consider rate cuts in the immediate future," said Matthew Martin, US economist at Oxford Economics.

"While we see the odds of the first rate cut occurring in September rising, cooler reports such as the PPI report keep the June meeting on the table, which is our current baseline."

Meanwhile, initial jobless claims in the US dropped to 211,000 in the week ended 6 April, marking the lowest reading in a month and undershooting market expectations, while continuing claims also decreased.

Closer to home, the European Central Bank (ECB) opted to maintain its current interest rates, signalling a cautious approach amid uncertainties surrounding inflation and geopolitical events.

ECB president Christine Lagarde emphasised the potential impact of geopolitical tensions on economic growth and prices, acknowledging the importance of energy price fluctuations in shaping inflation dynamics.

The ECB's stance remained contingent on future economic projections, with a willingness to adjust interest rates if needed to support price stability.

On home shores, the UK housing market showed signs of resilience, with buyer demand strengthening and house price trends improving.

According to the RICS UK residential survey, buyer demand reached its most positive level since February 2022 in March, while new instructions also increased.

House price trends continued to improve for the seventh consecutive month, indicating a stabilising market despite ongoing uncertainties.

"Demand continues to recover gradually across the UK housing market, with new buyer enquiries rising for a third month in succession," said Tarrant Parsons, senior economist at the Royal Institution of Chartered Surveyors.

"With the inflation backdrop turning a little less difficult of late, this has led to expectations that the Bank of England will be able to start lowering interest rates later in the year.

"This should continue to support the market to a certain degree going forward."

Ex-divs prove a big drag, Kingfisher rises on upgrade

On London's equity markets, ex-dividend stocks proved a major drag, with Aviva, Barratt Developments, Lloyds, Reckitt Benckiser, Phoenix Group, Smurfit Kappa, Man Group, Howden Joinery, Just Group, Savills, TP ICAP, Harbour Energy, Hunting and ITV all in the red as a result.

Travel shares were under pressure amid concerns over potential geopolitical tensions, with IAG, easyJet, Carnival, and Wizz Air Holdings all registering losses.

Jupiter Fund Management faced downward pressure following a downgrade from Barclays.

On the upside, B&Q and Castorama owner Kingfisher rose 2.44% after receiving an upgrade to 'buy' from HSBC.

AstraZeneca increased 2.14% after announcing a 7% rise in its annual dividend, while Great Portland Estates added 1.61% on the back of strong demand and expectations of a rate cut.

Cybersecurity specialist Darktrace jumped 5.82% after raising its guidance for the year following robust third-quarter results.

Elsewhere, Marks & Spencer received a boost after an upgrade from JPMorgan, while outside the FTSE 250, Lok'n Store Group rocketed 16.91% following an acquisition agreement with Belgian rival Shurgard.

Reporting by Josh White for Sharecast.com.

Market Movers

FTSE 100 (UKX) 7,923.80 -0.47%

FTSE 250 (MCX) 19,786.87 -0.08%

techMARK (TASX) 4,458.35 0.37%

FTSE 100 - Risers

Centrica (CNA) 130.30p 3.41%

Smiths Group (SMIN) 1,647.00p 2.68%

Kingfisher (KGF) 248.00p 2.44%

AstraZeneca (AZN) 10,962.00p 2.14%

Rightmove (RMV) 535.80p 1.90%

Unite Group (UTG) 937.50p 1.68%

Hikma Pharmaceuticals (HIK) 1,817.00p 1.62%

Imperial Brands (IMB) 1,701.50p 1.58%

SSE (SSE) 1,605.50p 1.32%

Intermediate Capital Group (ICP) 2,114.00p 1.25%

FTSE 100 - Fallers

Aviva (AV.) 458.80p -6.35%

Phoenix Group Holdings (PHNX) 511.00p -5.81%

Tesco (TSCO) 282.00p -5.05%

Lloyds Banking Group (LLOY) 50.66p -4.63%

International Consolidated Airlines Group SA (CDI) (IAG) 169.10p -3.67%

easyJet (EZJ) 547.20p -3.61%

Barclays (BARC) 183.64p -3.08%

Sainsbury (J) (SBRY) 259.80p -2.77%

HSBC Holdings (HSBA) 646.70p -2.49%

Reckitt Benckiser Group (RKT) 4,206.00p -2.30%

FTSE 250 - Risers

Darktrace (DARK) 466.20p 6.25%

Watches of Switzerland Group (WOSG) 373.00p 5.13%

Safestore Holdings (SAFE) 760.50p 4.54%

Drax Group (DRX) 497.20p 2.90%

Close Brothers Group (CBG) 483.40p 2.68%

Bytes Technology Group (BYIT) 510.00p 2.57%

Big Yellow Group (BYG) 1,044.00p 2.55%

Diversified Energy Company (DEC) 1,106.00p 2.50%

Centamin (DI) (CEY) 127.90p 2.32%

Workspace Group (WKP) 509.00p 2.22%

FTSE 250 - Fallers

TUI AG Reg Shs (DI) (TUI) 646.00p -4.58%

Man Group (EMG) 264.60p -3.85%

TP Icap Group (TCAP) 214.00p -3.83%

Savills (SVS) 1,020.00p -3.77%

W.A.G Payment Solutions (WPS) 68.80p -3.46%

ITV (ITV) 70.70p -3.42%

Wizz Air Holdings (WIZZ) 2,280.00p -3.14%

Jupiter Fund Management (JUP) 87.70p -3.09%

Carnival (CCL) 1,062.50p -2.88%

Aston Martin Lagonda Global Holdings (AML) 159.80p -2.80%

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.